#RA #ACR18 @RheumNow Abstr 838: Anti-MDA5 pos DM-ILD has a poor prognosis. survival at 6mo 89% vs 33% with combo imsuppressive (Pred 1mg/kg/d tapering, IVCYC 500-1g/m2; Tacrolimus through 24 wk. 29 pts, historic controls. Hi risk of CMV activation #ACR18 #Myositis @rheumnow